Integrin beta-like 1 is regulated by DNA methylation and increased in heart failure patients.
DNA methylation
Epigenetics
Heart failure
Ischaemic cardiomyopathy
Single nuclei RNA sequencing: cardiac fibroblasts
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
05 Sep 2024
05 Sep 2024
Historique:
revised:
17
07
2024
received:
22
04
2024
accepted:
21
08
2024
medline:
5
9
2024
pubmed:
5
9
2024
entrez:
5
9
2024
Statut:
aheadofprint
Résumé
Dynamic alterations in cardiac DNA methylation have been implicated in the development of heart failure (HF) with evidence of ischaemic heart disease (IHD); however, there is limited research into cell specific, DNA methylation sensitive genes that are affected by dysregulated DNA methylation patterns. In this study, we aimed to identify DNA methylation sensitive genes in the ischaemic heart and elucidate their role in cardiac fibrosis. A multi-omics integrative analysis was carried out on RNA sequencing and methylation sequencing on HF with IHD (n = 9) versus non-failing (n = 9) left ventricular tissue, which identified Integrin beta-like 1 (ITGBL1) as a gene of interest. Expression of Itgbl1 was assessed in three animal models of HF; an ischaemia-reperfusion pig model, a myocardial infarction mouse model and an angiotensin-II infused mouse model. Single nuclei RNA sequencing was carried out on heart tissue from angiotensin-II infused mice to establish the expression profile of Itgbl1 across cardiac cell populations. Subsequent in vitro analyses were conducted to elucidate a role for ITGBL1 in human cardiac fibroblasts. DNA pyrosequencing was applied to assess ITGBL1 CpG methylation status in genomic DNA from human cardiac tissue and stimulated cardiac fibroblasts. ITGBL1 was >2-fold up-regulated (FDR adj P = 0.03) and >10-fold hypomethylated (FDR adj P = 0.01) in human HF with IHD left ventricular tissue compared with non-failing controls. Expression of Itgbl1 was up-regulated in three isolated animal models of HF and showed conserved correlation between increased Itgbl1 and diastolic dysfunction. Single nuclei RNA sequencing highlighted that Itgbl1 is primarily expressed in cardiac fibroblasts, while functional studies elucidated a role for ITGBL1 in cardiac fibroblast migration, evident in 50% reduced 24 h fibroblast wound closure occurring subsequent to siRNA-targeted ITGBL1 knockdown. Lastly, evidence provided from DNA pyrosequencing supports the theory that differential expression of ITGBL1 is caused by DNA hypomethylation. ITGBL1 is a gene that is mainly expressed in fibroblasts, plays an important role in cardiac fibroblast migration, and whose expression is significantly increased in the failing heart. The mechanism by which increased ITGBL1 occurs is through DNA hypomethylation.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Heart Research UK
ID : RG2662
Organisme : British Heart Foundation
ID : PG/20/10424
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/18/21/33599
Pays : United Kingdom
Informations de copyright
© 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales‐Villa R, Basso C, et al. 2023 ESC guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J 2023;44:3503‐3626. doi:10.1093/eurheartj/ehad194
Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93 Preprint at: doi:10.1136/hrt.2003.025270
Khan MA, Hashim MJ, Mustafa H, Baniyas MY, Al Suwaidi SKBM, AlKatheeri R, et al. Global epidemiology of ischemic heart disease: results from the Global Burden of Disease Study. Cureus 2020;12:e9349. doi:10.7759/cureus.9349
Cabac‐Pogorevici I, Muk B, Rustamova Y, Kalogeropoulos A, Tzeis S, Vardas P. Ischaemic cardiomyopathy. Pathophysiological insights, diagnostic management and the roles of revascularisation and device treatment. Gaps and dilemmas in the era of advanced technology. Eur J Heart Fail 2020;22 Preprint at: doi:10.1002/ejhf.1747
Russell‐Hallinan A, Watson CJ, Baugh JA. Epigenetics of aberrant cardiac wound healing. Compr Physiol 2018;8: doi:10.1002/cphy.c170029
Hsu CC, Wang JS, Shyu YC, Fu TC, Juan YH, Yuan SS, et al. Hypermethylation of ACADVL is involved in the high‐intensity interval training‐associated reduction of cardiac fibrosis in heart failure patients. J Transl Med 2023;21:187. doi:10.1186/s12967‐023‐04032‐7
Glezeva N, Moran B, Collier P, Moravec CS, Phelan D, Donnellan E, et al. Targeted DNA methylation profiling of human cardiac tissue reveals novel epigenetic traits and gene deregulation across different heart failure patient subtypes. Circ Heart Fail 2019;12:e005765. doi:10.1161/CIRCHEARTFAILURE.118.005765
McLellan MA, Skelly DA, Dona MSI, Squiers GT, Farrugia GE, Gaynor TL, et al. High‐resolution transcriptomic profiling of the heart during chronic stress reveals cellular drivers of cardiac fibrosis and hypertrophy. Circulation 2020;142:1448‐1463. doi:10.1161/CIRCULATIONAHA.119.045115
Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE, Jenkins SL, et al. Gene set knowledge discovery with Enrichr. Curr Protoc 2021;1:e90. doi:10.1002/cpz1.90
Huang R, Grishagin I, Wang Y, Zhao T, Greene J, Obenauer JC, et al. The NCATS BioPlanet—an integrated platform for exploring the universe of cellular signaling pathways for toxicology, systems biology, and chemical genomics. Front Pharmacol 2019;10:445. doi:10.3389/fphar.2019.00445
Ren Z, Yu P, Li D, Li Z, Liao Y, Wang Y, et al. Single‐cell reconstruction of progression trajectory reveals intervention principles in pathological cardiac hypertrophy. Circulation 2020;141:1704‐1719. doi:10.1161/CIRCULATIONAHA.119.043053
Pepin ME, Ha CM, Crossman DK, Litovsky SH, Varambally S, Barchue JP, et al. Genome‐wide DNA methylation encodes cardiac transcriptional reprogramming in human ischemic heart failure. Lab Invest 2019;99:371‐386. doi:10.1038/s41374‐018‐0104‐x
Berg RW, Leung E, Gough S, Morris C, Yao WP, Wang SX, et al. Cloning and characterization of a novel β integrin‐related cDNA coding for the protein TIED ('ten β integrin EGF‐like repeat domains') that maps to chromosome band 13q33: a divergent stand‐alone integrin stalk structure. Genomics 1999;56:169‐178. doi:10.1006/geno.1998.5707
Takagi J, Beglova N, Yalamanchili P, Blacklow SC, Springer TA. Definition of EGF‐like, closely interacting modules that bear activation epitopes in integrin β subunits. Proc Natl Acad Sci U S A 2001;98:11175‐11180. doi:10.1073/pnas.201420198
Feng Y, Li X, Sun B, Wang Y, Zhang L, Pan X, et al. Evidence for a transcriptional signature of breast cancer. Breast Cancer Res Treat 2010;122:65‐75. doi:10.1007/s10549‐009‐0505‐z
Ji Q, Zhou L, Sui H, Yang L, Wu X, Song Q, et al. Primary tumors release ITGBL1‐rich extracellular vesicles to promote distal metastatic tumor growth through fibroblast‐niche formation. Nat Commun 2020;11:1211. doi:10.1038/s41467‐020‐14869‐x
Chen XQ, Li XT, Wu XY, Ding Y, Li Y, Zhou GQ, et al. Integrin beta‐like 1 mediates fibroblast‐cardiomyocyte crosstalk to promote cardiac fibrosis and hypertrophy. Cardiovasc Res 2023;119:1928‐1941. doi:10.1093/cvr/cvad104
Portokallidou K, Dovrolis N, Ragia G, Atzemian N, Kolios G, Manolopoulos VG. Multi‐omics integration to identify the genetic expression and protein signature of dilated and ischemic cardiomyopathy. Front Cardiovasc Med 2023;10:1115623. doi:10.3389/fcvm.2023.1115623
Wang HB, Huang R, Yang K, Xu M, Fan D, Liu MX, et al. Identification of differentially expressed genes and preliminary validations in cardiac pathological remodeling induced by transverse aortic constriction. Int J Mol Med 2019;44: doi:10.3892/ijmm.2019.4379
Watson JA, Watson CJ, Mccann A, Baugh J. Epigenetics, the epicenter of the hypoxic response. Epigenetics 2010;5:293‐296. doi:10.4161/epi.5.4.11684
Li W, Li S, Yang J, Cui C, Yu M, Zhang Y. ITGBL1 promotes EMT, invasion and migration by activating NF‐κB signaling pathway in prostate cancer. Onco Targets Ther 2019;12:10693‐10701. doi:10.2147/OTT.S200082
Huang W, Yu D, Wang M, Han Y, Lin J, Wei D, et al. ITGBL1 promotes cell migration and invasion through stimulating the TGF‐β signalling pathway in hepatocellular carcinoma. Cell Prolif 2020;53:e12836. doi:10.1111/cpr.12836
Li XQ, du X, Li DM, Kong PZ, Sun Y, Liu PF, et al. ITGBL1 is a Runx2 transcriptional target and promotes breast cancer bone metastasis by activating the TGFβ signaling pathway. Cancer Res 2015;75:3302‐3313. doi:10.1158/0008‐5472.CAN‐15‐0240
Gan X, Liu Z, Tong B, Zhou J. Epigenetic downregulated ITGBL1 promotes non‐small cell lung cancer cell invasion through Wnt/PCP signaling. Tumor Biol 2016;37:8461. doi:10.1007/s13277‐016‐4834‐3
Lian XY, Ma JC, Zhou JD, Zhang TJ, Wu DH, Deng ZQ, et al. Hypermethylation of ITGBL1 is associated with poor prognosis in acute myeloid leukemia. J Cell Physiol 2019;234:9438‐9446. doi:10.1002/jcp.27629
Khan SS, Beach LB, Yancy CW. Sex‐based differences in heart failure: JACC focus seminar 7/7. J Am Coll Cardiol 2022;79 Preprint at: doi:10.1016/j.jacc.2022.02.013
Van Eickels M, Rolf S, Doevendans PA, Meyer R, Grohé C, Schlüter KD. The influence of oestrogen‐deficiency and ACE inhibition on the progression of myocardial hypertrophy in spontaneously hypertensive rats. Eur J Heart Fail 2005;7:1079‐1084. doi:10.1016/j.ejheart.2005.03.004